Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
Author:
Affiliation:
1. Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2277915
Reference25 articles.
1. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
2. A note from history: Landmarks in history of cancer, Part 6
3. Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
4. The biology of erbB-2/nue/HER-2 and its role in cancer
5. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates;American Society of Clinical Oncology Educational Book;2024-06-01
2. Biomarkers for Antibody–Drug Conjugates in Solid Tumors;Molecular Cancer Therapeutics;2024-02-02
3. Using antibody-drug conjugates for anti-tumor immunity;Reference Module in Life Sciences;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3